Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436267 | 0.91 | MAPT (0.49) | TP53MAPTCNR1KMT2AMEN1 | |
| SCHEMBL12643221 | 0.91 | MAPT (0.49) | TP53MAPTCNR1KMT2AMEN1 | |
| SCHEMBL12643198 | 0.86 | KMT2A (0.49) | TP53MAPTCNR1KMT2AMEN1 | |
| SCHEMBL14668234 | 0.83 | LMNA (0.46) | MAPTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL31587941 | 0.78 | KMT2A (0.55) | MAPTCNR1KMT2AMEN1RXFP1 | |
| SCHEMBL32672556 | 0.78 | SMO (0.44) | NPC1SLC6A9 | |
| SCHEMBL30511079 | 0.78 | GAA (0.53) | ALDH1A1NPC1SLC6A9 | |
| SCHEMBL17636193 | 0.78 | GAA (0.53) | ALDH1A1NPC1SLC6A9 | |
| SCHEMBL32672541 | 0.76 | SLC6A9 (0.44) | TP53SLC6A9 | |
| SCHEMBL32672593 | 0.74 | SMO (0.47) | TP53KMT2AMEN1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036305-A1 | Method of treating peripheral neuropathy | CHEMEDEST LTD. (EE) | 2018-02-08 | — | — | US | disclosed |
| US-20160136159-A1 | Method for Treating Peripheral Neuropathy | CHEMEDEST LTD. (EE) | 2016-05-19 | — | — | US | disclosed |
| US-8901129-B2 | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators | GENECODE AS (EE) | 2014-12-02 | — | — | US | disclosed |
| US-20130030180-A1 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators | GENECODE AS (EE) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136159-A1 | Method for Treating Peripheral Neuropathy | GFRA3, GAP43, GFRA2 | TP53 4839/4885MAPT 2102/4885CNR1 420/4885 |
| US-20180036305-A1 | Method of treating peripheral neuropathy | GFRA3, GFRA2, GAP43 | TP53 4839/4885MAPT 1931/4885CNR1 406/4885 |
| US-20130030180-A1 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators | GFRA2, GFRA1, GFRA3 | TP53 3789/4885MAPT 1067/4885CNR1 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.